

CLAIMS

1. A method for treating neurodegenerative disease, comprising:
introducing an agent to stimulate expression of a non-amyloidogenic
5 protein.

2. The method of claim 1, wherein the neurodegenerative
disease comprises neurodegenerative diseases from the group consisting
of Alzheimer's disease, Parkinson's disease and Lewy body disease.
10

3. The method of claim 1, wherein the non-amyloidogenic
protein is β -synuclein.

4. A method for screening treatments for neurodegenerative
15 disease, comprising:
stimulating oxidative stress;
measuring aggregation of NACP/ α -synuclein in neuronal cells; and
second measuring aggregation of NACP/ α -synuclein to test for a
decrease in aggregation, wherein the decrease is indicative of an effective
20 treatment.

5. The method of claim 4, wherein oxidative stress is stimulated
by a mixture of metal-ions and hydrogen peroxide.

25 6. The method of claim 4, wherein oxidative stress is stimulated
using an iron-catalyzed oxidative reaction.

7. The method of claim 4, wherein expression of a non-
amyloidogenic protein modulates aggregation of NACP/ α -synuclein.

8. The method of claim 7, wherein the non-amyloidogenic protein is β -synuclein.

5 9. A method for screening treatments of neurodegenerative disease comprising evaluating agents for stimulation of expression of a non-amyloidogenic protein.

10. The method of claim 9, wherein the non-amyloidogenic protein is β -synuclein.